Mutations Associated With a Complex Phenotype Resembling Dopa-Responsive Dystonia

Overview

Journal Mov Disord Clin Pract

Publisher Wiley

Specialty Neurology

Date 2018 Oct 27

PMID 30363882

Citations 7

Authors

Subhashie Wijemanne

Joshua M Shulman

Joohi Jimenez-Shahed

Daniel Curry

Joseph Jankovic

Affiliations

Soon will be listed here.

Abstract

Background: The aim of this study was to describe a case of hereditary spastic paraplegia (HSP) resulting from mutations, presenting with a complex phenotype of dopa-responsive dystonia (DRD), diagnosed using whole exome sequencing (WES). HSP resulting from typically presents with spasticity, cognitive impairment, and radiological evidence of thin corpus callosum. Initial presentation with DRD has not been previously reported on.

Methods: This 11-year-old boy with delay in fine motor skills, presented at 8 years of age with progressive, generalized dystonia with diurnal variation, bradykinesia, and stiff gait. There was marked improvement in dystonia with levodopa, but he soon developed wearing-off phenomenon and l-dopa-induced dyskinesia. Family history was unremarkable.

Results: Brain MRI showed thinning of the anterior corpus callosum with periventricular white matter changes. I-ioflupane single-photon emission coupled tomography showed bilateral severe presynaptic dopamine deficiency. WES identified transheterozygous allelic variants in the on chromosome 15, including a truncating STOP mutation (p.E1630X) and a second heterozygous coding variant (p.L2300R). Dystonia improved with globus pallidus internus (GPi) DBS surgery.

Conclusions: HSP resulting from should be considered in the differential diagnosis of a patient presenting with DRD, parkinsonism, and spasticity. This case expands the HSP genotype and phenotype. GPi DBS may be a therapeutic option in selected patients.

Citing Articles

Clinically approved immunomodulators ameliorate behavioral changes in a mouse model of hereditary spastic paraplegia type 11.

Horner M, Popp S, Branchu J, Stevanin G, Darios F, Klebe S Front Neurosci. 2024; 18:1299554.

PMID: 38435059 PMC: 10904495. DOI: 10.3389/fnins.2024.1299554.

Movement disorders in hereditary spastic paraplegias.

Pedroso J, Vale T, Freitas J, Araujo F, Meira A, Neto P Arq Neuropsiquiatr. 2023; 81(11):1000-1007.

PMID: 38035585 PMC: 10689114. DOI: 10.1055/s-0043-1777005.

Movement disorders in hereditary spastic paraplegia (HSP): a systematic review and individual participant data meta-analysis.

Fereshtehnejad S, Saleh P, Oliveira L, Patel N, Bhowmick S, Saranza G Neurol Sci. 2022; 44(3):947-959.

PMID: 36441344 PMC: 9925593. DOI: 10.1007/s10072-022-06516-8.

Recent advances in understanding hereditary spastic paraplegias and emerging therapies.

Lallemant-Dudek P, Darios F, Durr A Fac Rev. 2021; 10:27.

PMID: 33817696 PMC: 8009193. DOI: 10.12703/r/10-27.

Parkinsonism and Positive Dopamine Transporter Imaging in a Patient with a Novel KMT2B Variant.

Feuerstein J, Taylor M, Kwak J, Berman B Mov Disord Clin Pract. 2021; 8(2):279-281.

PMID: 33816656 PMC: 8008275. DOI: 10.1002/mdc3.13140.

References

Vanderver A, Tonduti D, Auerbach S, Schmidt J, Parikh S, Gowans G . Neurotransmitter abnormalities and response to supplementation in SPG11. Mol Genet Metab. 2012; 107(1-2):229-33. PMC: 3517733. DOI: 10.1016/j.ymgme.2012.05.020. View

Stevanin G, Santorelli F, Azzedine H, Coutinho P, Chomilier J, Denora P . Mutations in SPG11, encoding spatacsin, are a major cause of spastic paraplegia with thin corpus callosum. Nat Genet. 2007; 39(3):366-72. DOI: 10.1038/ng1980. View

Naumann M, Pirker W, Reiners K, Lange K, Becker G, Brucke T . [123I]beta-CIT single-photon emission tomography in DOPA-responsive dystonia. Mov Disord. 1997; 12(3):448-51. DOI: 10.1002/mds.870120330. View

Ramensky V, Bork P, Sunyaev S . Human non-synonymous SNPs: server and survey. Nucleic Acids Res. 2002; 30(17):3894-900. PMC: 137415. DOI: 10.1093/nar/gkf493. View

Murmu R, Martin E, Rastetter A, Esteves T, Muriel M, El Hachimi K . Cellular distribution and subcellular localization of spatacsin and spastizin, two proteins involved in hereditary spastic paraplegia. Mol Cell Neurosci. 2011; 47(3):191-202. DOI: 10.1016/j.mcn.2011.04.004. View

Bainbridge M, Wiszniewski W, Murdock D, Friedman J, Gonzaga-Jauregui C, Newsham I . Whole-genome sequencing for optimized patient management. Sci Transl Med. 2011; 3(87):87re3. PMC: 3314311. DOI: 10.1126/scitranslmed.3002243. View

Lo Giudice T, Lombardi F, Santorelli F, Kawarai T, Orlacchio A . Hereditary spastic paraplegia: clinical-genetic characteristics and evolving molecular mechanisms. Exp Neurol. 2014; 261:518-39. DOI: 10.1016/j.expneurol.2014.06.011. View

Crosby A, Patel H, Chioza B, Proukakis C, Gurtz K, Patton M . Defective mitochondrial mRNA maturation is associated with spastic ataxia. Am J Hum Genet. 2010; 87(5):655-60. PMC: 2978972. DOI: 10.1016/j.ajhg.2010.09.013. View

Hanihara T, Inoue K, Kawanishi C, Sugiyama N, Miyakawa T, Onishi H . 6-Pyruvoyl-tetrahydropterin synthase deficiency with generalized dystonia and diurnal fluctuation of symptoms: a clinical and molecular study. Mov Disord. 1997; 12(3):408-11. DOI: 10.1002/mds.870120321. View

10.

Stevanin G, Azzedine H, Denora P, Boukhris A, Tazir M, Lossos A . Mutations in SPG11 are frequent in autosomal recessive spastic paraplegia with thin corpus callosum, cognitive decline and lower motor neuron degeneration. Brain. 2007; 131(Pt 3):772-84. DOI: 10.1093/brain/awm293. View

11.

Paisan-Ruiz C, Nath P, Wood N, Singleton A, Houlden H . Clinical heterogeneity and genotype-phenotype correlations in hereditary spastic paraplegia because of Spatacsin mutations (SPG11). Eur J Neurol. 2008; 15(10):1065-70. PMC: 7254873. DOI: 10.1111/j.1468-1331.2008.02247.x. View

12.

Burke R, Fahn S, Marsden C, Bressman S, Moskowitz C, Friedman J . Validity and reliability of a rating scale for the primary torsion dystonias. Neurology. 1985; 35(1):73-7. DOI: 10.1212/wnl.35.1.73. View

13.

Rajput A, Gibb W, Zhong X, Shannak K, Kish S, Chang L . Dopa-responsive dystonia: pathological and biochemical observations in a case. Ann Neurol. 1994; 35(4):396-402. DOI: 10.1002/ana.410350405. View

14.

Clot F, Grabli D, Cazeneuve C, Roze E, Castelnau P, Chabrol B . Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with Dopa-responsive dystonia. Brain. 2009; 132(Pt 7):1753-63. DOI: 10.1093/brain/awp084. View

15.

Siri L, Battaglia F, Tessa A, Rossi A, Di Rocco M, Facchinetti S . Cognitive profile in spastic paraplegia with thin corpus callosum and mutations in SPG11. Neuropediatrics. 2010; 41(1):35-8. DOI: 10.1055/s-0030-1253352. View

16.

Richards C, Bale S, Bellissimo D, Das S, Grody W, Hegde M . ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genet Med. 2008; 10(4):294-300. DOI: 10.1097/GIM.0b013e31816b5cae. View

17.

Paisan-Ruiz C, Guevara R, Federoff M, Hanagasi H, Sina F, Elahi E . Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations. Mov Disord. 2010; 25(12):1791-800. PMC: 6005705. DOI: 10.1002/mds.23221. View

18.

Zhao W, Zhu Q, Zhang J, Liu H, Wang L, Chen Z . Exome sequencing identifies novel compound heterozygous mutations in SPG11 that cause autosomal recessive hereditary spastic paraplegia. J Neurol Sci. 2013; 335(1-2):112-7. DOI: 10.1016/j.jns.2013.09.004. View

19.

Asmus F, Gasser T . Dystonia-plus syndromes. Eur J Neurol. 2010; 17 Suppl 1:37-45. DOI: 10.1111/j.1468-1331.2010.03049.x. View

20.

Wilder-Smith E, Tan E, Law H, Zhao Y, Ng I, Wong M . Spinocerebellar ataxia type 3 presenting as an L-DOPA responsive dystonia phenotype in a Chinese family. J Neurol Sci. 2003; 213(1-2):25-8. DOI: 10.1016/s0022-510x(03)00129-1. View